论文部分内容阅读
目的 :观察霉酚酸酯 (MMF)在预防肾移植术后近期 (3个月 )急性排斥反应 (AR)的情况。方法 :将 112例患者随机分成 2组 ,MMF(2 .0 g/d)组和硫唑嘌呤 (Aza)组。两组患者均同时接受相似剂量的环孢素 A和类固醇激素治疗。结果 :观察 3个月 ,MMF组 6 0例 ,AR发生率为 16 .7% (10 /6 0 ) ,Aza组 5 2例 ,AR发生率为 42 .3%(2 2 /5 2 ) ,两组差异有极显著意义 (P <0 .0 1)。 MMF组 5例出现血白细胞、血小板等不同程度下降 ,3例出现腹泻 ,在 MMF减量或停药后均恢复正常 ,未见有 MMF引起的肝、肾功能异常病例 ;Aza组有 9例出现肝功能损害。结论 :MMF具有预防和减少肾移植术后近期 AR效果 ,MMF的安全性可靠 ,副作用轻且为可逆性。
Objective: To observe the effect of mycophenolate mofetil (MMF) in the prevention of acute rejection (AR) in the near future (3 months) after renal transplantation. Methods: One hundred and twelve patients were randomly divided into two groups: MMF (2.0 g / d) and azathioprine (Aza) groups. Both groups received concurrent doses of cyclosporine A and a steroid hormone. Results: Six months after MMF, the incidence of AR was 16.7% (10/60) in the MMF group, 52 cases in the Aza group and 42.3% (22/52) in the Aza group, There was significant difference between the two groups (P <0.01). MMF group 5 cases of blood leukocytes, platelets and other varying degrees of decline in 3 cases of diarrhea, MMF reduction or withdrawal were back to normal, no MMF-induced liver and kidney dysfunction cases; Aza group of 9 patients Liver damage. CONCLUSION: MMF can prevent and reduce the recent AR effects after renal transplantation. MMF is reliable, mild and reversible.